Cougar Biotechnology Appoints Samuel Saks to Board of Directors.

LOS ANGELES -- Cougar Biotechnology, Inc. (OTCBB:CGRB) today announced the appointment of Samuel R. Saks, M.D. to the Company's Board of Directors. Dr. Saks is a board certified medical oncologist with over 25 years of experience in the clinical and academic settings. He currently serves as Chief Executive Officer of Jazz Pharmaceuticals, Inc., a publicly held specialty pharmaceuticals company that he co-founded in 2003.

Prior to joining Jazz Pharmaceuticals, Dr. Saks held a number of positions at Alza Corporation, which was acquired by Johnson & Johnson in 2001. From 2001 to 2003, he was Company Group Chairman of Alza and served as a member of Johnson & Johnson's Pharmaceutical Group Operating Committee. From 1992 to 2001, he held various executive positions at Alza, including Chief Medical Officer and Group Vice President, where he was responsible for clinical and commercial activities. He has also held clinical research positions in oncology at Schering-Plough Corporation, XOMA Corporation and Genentech, Inc. From 1987 to 2000, Dr. Saks was Assistant Clinical Professor of Medicine in the oncology division of the Department of Medicine at the University of California, San Francisco.

Dr. Arie S. Belldegrun, M.D., FACS, Vice Chairman of the Board of Directors of Cougar Biotechnology, said, "Sam brings to Cougar an impressive track record from a distinguished career dedicated to the study and treatment of cancer. We are confident that his extensive experience in successfully developing and commercializing novel therapeutic products will be of great benefit to Cougar's Board of Directors and senior management team."

Alan H. Auerbach, Chief Executive Officer and President of Cougar Biotechnology, added, "We are extremely pleased to welcome to our Board an executive with Sam's outstanding leadership abilities and commitment to clinical oncology. Sam's insight into the complexities of drug development targeting advanced disease conditions will be invaluable in helping us to achieve our strategic objectives."

In addition to board membership at Jazz Pharmaceuticals, Dr. Saks also serves as a director of Trubion Pharmaceuticals, Inc., a publicly held biopharmaceutical company based in Seattle, which focuses on the discovery, development and commercialization of medicines to treat inflammatory disease and cancer. Dr. Saks received a B.S. and an M.D. from the University of Illinois. He is board certified in oncology and a diplomat of the American Board of Internal Medicine.

About Cougar Biotechnology

Cougar Biotechnology, Inc. is a Los Angeles-based biotechnology company established to in-license and develop clinical stage drugs, with a specific focus on the field of oncology. Cougar's oncology portfolio includes CB7630, a targeted inhibitor of the 17-alpha hydroxylase/c17,20 lyase enzyme, which is currently being tested in Phase II clinical trials in prostate cancer; CB3304, an inhibitor of microtubule dynamics, which is currently in a Phase I trial in hematological malignancies and CB1089, an analog of vitamin D, which has been clinically tested in a number of solid tumor types.

Further information about Cougar Biotechnology can be found at www.cougarbiotechnology.com.

This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. These statements are often, but not always, made through the use of words or phrases such as "anticipates," "expects," "plans," "believes," "intends," and similar words or phrases. Such statements involve risks and uncertainties that could cause Cougar's actual results to differ materially from the anticipated results and expectations expressed in these forward-looking statements. These statements are only predictions based on current information and expectations and involve a number of risks and uncertainties. Actual events or results may differ materially from those projected in any of such statements due to various factors, including the risks and uncertainties inherent in clinical trials, and drug development and commercialization, including the uncertainty of whether results in testing of CB7630 will be predictive of results in later stages of development. For a discussion of these and other factors, please refer to Cougar's annual report on Form 10-KSB for the year ended December 31, 2006 as well as other subsequent filings with the Securities and Exchange Commission. You are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date hereof. This caution is made under the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. All forward-looking statements are qualified in their entirety by this cautionary statement and Cougar undertakes no obligation to revise or update this press release to reflect events or circumstances after the date hereof.